Grifols acquired 26% interest in Shanghai RAAS Blood Products, pharmaceutical company specialized in the research, manufacture and sale of plasma derived products for therapeutic use, in exchange for a non-majority share (45% economic and 40% voting rights) in Grifols Diagnostic Solutions, for $1.9bn. This alliance is an important step forward in Grifols' sustainable growth and long-term strategy, generating value for all of its divisions, particularly the Bioscience and Diagnostic Divisions. In exchange, the agreement will enable Shanghai RAAS to diversify its business with the support of a global leader in NAT technology and other innovative diagnostic solutions.